Quetiapine goes first, hydroxyzine second and clonazepam onto a separate taper plan in the NU675 Unit 4 review of seven psychiatric agents taken by a composite retired officer with PTSD. Searches like "nu 675 unit 4 assignment example", "nu675 unit 4 sample" and "nu675 unit 4 example" land here.
What a finished NU675 Unit 4 polypharmacy review looks like
A seven-row review table followed by three pages of reasoning and a sequenced plan. Columns read agent, year added and original reason, current target, evidence it is helping now, harms in this man, and verdict. Fluoxetine keeps its place as the agent aimed at PTSD itself. Prazosin's row cites Raskind and colleagues (2018), whose trial in veterans with chronic PTSD found no benefit over placebo for nightmares, and sets that against his own nightmare log. Clonazepam's row cites the VA/DoD guideline's position against benzodiazepines in PTSD, carried into its 2023 edition. Quetiapine and trazodone are found to target the same symptom, sleep, while his A1c of [6.1] and BMI of [33] are charged to quetiapine. Hydroxyzine is used [twice a month]. Gabapentin's target turns out to be back pain, prescribed by his primary care clinician.
How a NU675 Unit 4 example is structured
Every agent is asked the same four questions: what is it treating now, is there evidence it is still helping, what is it costing him, and does another agent on the list already do its job. Identical questions expose the duplication, since quetiapine and trazodone answer the first one with the same word. Verdicts come in four kinds, keep, reduce, stop or clarify, and each carries its reason. The plan then sequences changes one at a time at [four-week] intervals, starting where harm is highest and withdrawal risk lowest, so that any change in sleep or mood can be traced to a single step. Clonazepam is placed last and handed to its own taper plan. A non-drug section recommends trauma-focused psychotherapy and a sleep study, since loud snoring and a STOP-Bang score of [5] point to untreated apnea.
Four questions for every agent
Current target, evidence of benefit, cost to him and overlap with another agent are asked of all seven medicines alike. Applying one test to each keeps the review from sparing an agent simply because it has been there longest.
Two drugs, one symptom
Quetiapine and trazodone were both added for sleep, years apart and by different clinicians. Identifying the duplication is the review's central finding, and quetiapine is chosen for removal because its metabolic cost is already visible in his labs.
A trial that changed the evidence
Prazosin was a common choice for nightmares until a large 2018 trial in veterans found no benefit. The review does not stop it on that basis alone; it asks for [four weeks] of his own nightmare log before any reduction.
The benzodiazepine saved for last
Clonazepam carries the most withdrawal risk and the clearest guideline objection. The review explains why it is reduced last rather than first: removing it while other sedatives are changing would make every symptom impossible to attribute.
What the list was missing
Trauma-focused psychotherapy, never offered in [eight] years, and a sleep study for probable apnea are added. The review notes that either could make several medicines unnecessary, which is why both appear before the reductions begin.
Where marks go in NU675 Unit 4
A review that justifies everything and removes nothing is the result graders see most and credit least, because the exercise exists to test each agent, not to defend the list. Overlooking the quetiapine and trazodone overlap costs heavily as well, since it is obvious once each agent's current target is written down. Stopping several agents at once draws a safety comment and a methodological one: no symptom change afterward could be traced to a cause. Clonazepam handled carelessly costs marks either way, left untouched without comment or withdrawn abruptly. Graders expect the evidence cited accurately, with the prazosin trial described in its population and the guideline dated. Sleep apnea unmentioned despite the snoring, psychotherapy absent and gabapentin changed without asking its prescriber make up the lesser deductions.
Get a NU675 Unit 4 example written to your instructions
List every medication in your NU675 Unit 4 case, with whatever history the prompt gives for each, and attach the rubric. Within 24-48h your first custom review arrives free: each agent asked what it treats today, a verdict with its reason, and reductions sequenced one at a time so a later change can be traced.
NU675 Unit 4 questions, answered
How many changes should a polypharmacy review recommend at once?
Usually singly, with an interval long enough to see each effect. Changing several agents together makes it impossible to tell which change caused a new symptom or a relief, and it multiplies withdrawal risk. Sequence the changes, say why each comes where it does, and state what would pause the sequence.
Should the review change medicines another clinician prescribed?
Not unilaterally. Identify the agent, its target and any concern, then recommend a conversation with the prescriber, as this review does with gabapentin for back pain. Graders credit recognizing where a decision belongs. A review that stops another clinician's medication without contact reads as overstepping, even when the reasoning behind the concern is sound.
Where do non-drug treatments fit in a polypharmacy review?
Often at the center. An untreated condition, such as sleep apnea, or a missing first-line therapy, such as trauma-focused psychotherapy for PTSD, can explain why medications accumulated. Naming those gaps shows why some agents may no longer be needed once the underlying problem is addressed, and it stops the review reading as a tally of subtractions.